«

»

It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.

However, it would have been interesting had Novartis followed the plan initially outlined by Meanwell which would likely have benefited millions more patients. The high price of Leqvio won’t allow for that.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive